Shots:

• The P-III JAVELIN Ovarian 100 study involves assessing of avelumab + and/or following Pt-based carboplatin/paclitaxel CT in 998 patients with LA or metastatic (Stage III or Stage IV) epithelial ovarian cancer- fallopian tube cancer (FTC)- or primary peritoneal cancer
• The study resulted in unmet 1EPs as PFS and has shown no new safety signals with consistent safety profile
• Avelumab is anti-programmed death ligand-1 (PD-L1) Ab that blocks its interaction with PD-L1 with PD-1 receptors. In- 2014 Merck and Pfizer collaborates to co-develop and co-commercialize avelumab

Ref: Pfizer | Image: Buzzercast